Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
128.3 USD | -1.35% | +0.54% | +17.64% |
03:02pm | Merck: phase 3 trial in melanoma halted | CF |
02:05pm | Merck Ends Co-Formulation Arm of Keytruda High-Risk Melanoma Study | DJ |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.64% | 329B | |
+29.29% | 684B | |
+30.34% | 568B | |
-3.91% | 361B | |
+4.08% | 284B | |
+16.21% | 240B | |
+9.66% | 208B | |
-6.83% | 200B | |
+7.16% | 166B | |
-1.40% | 159B |
- Stock Market
- Equities
- MRK Stock
- News Merck & Co., Inc.
- Transcript : Merck & Co., Inc. Presents at UBS Biopharma Conference 2023, Nov-08-2023 12